IAG & Takeda Partner in Ulcerative Colitis Histopathological Image Analysis
Image Analysis Group (IAG) and Takeda Pharmaceutical Company Limited have made significant progress in their partnership to develop an AI-powered tool for histopathological image analysis in ulcerative colitis (UC). Since the initial announcement in 2017, the collaboration has advanced through several key milestones:
-
Development and Validation: The AI tool has been trained and tested on 200 images, demonstrating performance comparable to human experts.
-
Clinical Implementation: The partners have engaged eight world-leading sites to test the AI tool in clinical practice.
-
International Expansion: The collaboration now includes prominent clinical centers and opinion leaders from Switzerland, France, Canada, USA, Israel, Portugal, Brazil, and other countries
-
Publication of Results: A full manuscript detailing the AI-driven scoring system was published in April 2024 in the United European Gastroenterology Journal.
-
Ongoing Research: The project continues to evolve, with presentations scheduled at major conferences like Digestive Disease Week 2024.
The AI tool aims to provide gastroenterologists with an automated, accurate, and reliable method for evaluating disease activity in UC patients. This advancement has the potential to improve clinical decision-making, particularly in areas with limited access to trained IBD pathologists.
Dr. Olga Kubassova, President of IAG, continues to emphasize the company’s commitment to making AI truly useful in clinical decision-making and research. The collaboration between IAG and Takeda represents a significant step towards precision medicine in gastroenterology, with the ultimate goal of delivering the right treatment to the right patients at the right time.